Source comparison
How to Use Sermorelin for Body Composition Protocol: Comparison
Nightly Dose 200–300mcg subcutaneous, 30 min before sleep 400–500mcg subcutaneous, 30 min before sleep JCEM 2019: 300mcg produced 3.2kg lean mass gain over 12 weeks Conservative dose sufficient for most. Aggressive dosing increases side effect risk without pro
This comparison does not assign a generated winner or score.
- Nightly Dose
- 200–300mcg subcutaneous, 30 min before sleep
- 400–500mcg subcutaneous, 30 min before sleep
- JCEM 2019: 300mcg produced 3.2kg lean mass gain over 12 weeks
- Conservative dose sufficient for most. Aggressive dosing increases side effect risk without proportional benefit
- IGF-1 Target Range
- 250–300ng/ml (mid-normal range)
- 300–350ng/ml (upper-normal range)
- IGF-1 levels >400ng/ml correlate with increased insulin resistance (Endocrine Reviews 2020)
- Mid-range targets balance anabolic effects with metabolic safety. Upper-range targets appropriate only with frequent monitoring
- Administration Frequency
- Nightly, 7 days/week
- 5 days on, 2 days off (weekend cycling)
- Continuous administration maintains stable IGF-1 elevation; cycling reduces cumulative exposure but lowers consistency
- Continuous protocol produces more predictable results. Cycling appropriate for long-term protocols (>6 months) to prevent receptor downregulation
- Fasting Window Before Injection
- 2 hours minimum
- 3–4 hours for maximal GH pulse
- Insulin and glucose suppress GH release via hypothalamic feedback (J Clin Invest 1998)
- 2-hour fast sufficient. Extending to 4 hours offers marginal benefit unless baseline insulin sensitivity is impaired
- Reconstitution Stability
- Use within 21 days of mixing
- Use within 28 days (max FDA stability)
- Bacteriostatic water preserves peptide integrity for 28 days at 2–8°C; degradation accelerates after day 21
- 21-day window conservative and ideal for smaller vials. 28-day maximum acceptable if refrigeration maintained